Aculys Pharma - Crunchbase Company Profile & Funding

Q: Where is Aculys Pharma's headquarters?

Aculys Pharma is located in Tokyo, Tokyo, Japan.

Q: Who invested in Aculys Pharma?

Aculys Pharma has 11 investors including ANRI And Sumitomo Mitsui Trust Investment.

Q: When was the last funding round for Aculys Pharma?

Aculys Pharma closed its last funding round on obfuscated from a Series B round.

Q: How much funding has Aculys Pharma raised to date?

Aculys Pharma has raised obfuscated.

Overview

Aculys Pharma

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Aculys Pharma

CB Rank

55086

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Acquired by

Viatris

Founded

obfuscation

Private

Series B

Tokyo, Tokyo, Japan

11-50

aculys.com/ja/

Manufacturing

Medical

Neuroscience

Pharmaceutical

Funding Rounds

Series B

OBF

obfuscation

Series A

OBF

obfuscation

Key People

Hidemasa Tanigaki: Chief Executive Officer & Representative Director

Details

Sub-Organization of

Viatris

Legal Name

Aculys Pharma, Inc.

Also Known As

Aculys, アキュリスファーマ

Operating Status

Active

Company Type

For Profit

Founders

BT Slingsby, Kazunari Tsunaba, Takeshi Takahashi

About the Company

Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Pitolisant

A histamine H3 receptor antagonist/inverse agonist used to treat narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome (OSAS).

Diazepam Nasal Spray (NRL-1)

A nasal spray formulation of diazepam for emergency treatment of seizures, including status epilepticus and seizure clusters, in patients aged 6 and above.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B
obfuscated obfuscation	Series B - Aculys Pharma	10	obfuscated obfuscation	—	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
ANRI	—	Series B - Aculys Pharma	—
ANRI	—	Series B - Aculys Pharma	—
ANRI	—	Series B - Aculys Pharma	—
ANRI	—	Series B - Aculys Pharma	—
ANRI	—	Series B - Aculys Pharma	—